Company Overview and News


Add VRX
to your dashboard

Headline News

Valeant Pharmaceuticals Intl Inc Stock Rides High as More Good News Awaits

2018-01-17 investorplace
Showering its investors with good news, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is trading close to its yearly highs. Since early November, VRX stock has more than doubled, and for good reason. (164-0)

Judge Signals He Will Approve $290 Million Settlement Between Allergan Shareholders and Pershing, Valeant - WSJ

2018-01-16 wsj
A federal judge signaled Tuesday he would approve a $290 million settlement reached by Pershing Square Capital Management, Valeant Pharmaceuticals International Inc. and the shareholders of Allergan PLC who had alleged the two firms improperly profited from their failed attempt to buy the maker of Botox. (232-0)

Strong UnitedHealth Group Inc Earnings Keep Rally Going

2018-01-16 investorplace
It’s exceedingly difficult to find something to dislike about UnitedHealth Group Inc (NYSE:UNH) stock. In a healthcare sector filled with minefields over the past few years, UnitedHealth stock has tripled over the past four years. Valuation might seem a slight concern, but UNH stock isn’t that expensive on an earnings basis, nor is its balance sheet particularly levered. (353-0)

Worst Year Ever: Bill Ackman Or Eddie Lampert?

2018-01-14 seekingalpha
Bill Ackman has continued to suffer loss after loss with his investments: Valeant Pharmaceuticals (NYSE:VRX) got crushed, Chipotle Mexican Grill (NYSE:CMG) got crushed, and Herbalife (NYSE:HLF), his much hyped up short, has doubled. In fact, Ackman's fund, Pershing Square (OTCPK:PSHZF), fully divested the stock position in November because he's not an idiot. Instead, he bought the Put contacts, capping his losses, but still aligning his interests squarely with the collapse of the stock. (232-3)

SA Interview: Healthcare Investing With Paul Nouri, CFP

2018-01-14 seekingalpha
How to find companies with predictable cash flow and a strong pipeline, when a large cash balance should be discounted and why a company announcing that it is exploring strategic alternatives is not always a positive are topics discussed. (511-1)

Buy Pershing Square At A 25% Discount To Net Asset Value

2018-01-12 seekingalpha
It is headed by an accomplished star manager who recently got his concentrated portfolio in trouble. (305-3)

Is Valeant Pharmaceuticals Intl Inc a Buy? 3 Pros, 3 Cons

2018-01-11 investorplace
Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has been on a tear in recent months, nearly doubling since November 1, when it closed at $11.93 a share. It performed well in the third quarter. Valeant announced its results on November 7, with the news it beat analyst estimates for both revenue and net income. (169-0)

Askeladden Capital - Q4 2017 Letter: 'Trust The Process'

2018-01-11 seekingalpha
Not all great years look the same on paper; 2017 was a great year (in many ways better for our long-term future than 2016), but the numbers don't reflect that. Our reported performance in 2017 was roughly -2% (negative two percent) gross and -4% (negative four percent) net, compared to a +15% (positive fifteen percent) return for our S&P 1000 Total Return benchmark. Although I don't want to get into the habit of discussing performance intra-quarter, let alone intra-month, I feel like recent circumstances make it important to offer a caveat. (185-1)

Valeant Pharmaceuticals Intl Inc Stock Is Worth the Risk

2018-01-11 investorplace
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has begun a turnaround. The Laval, Canada-based drug manufacturer is on a growth path again after VRX stock came crashing from lofty highs. A new CEO now works to drive profits and reduce a heavy debt burden. (190-0)

Valeant's 'Significant Seven' Aren't Quite Magnificent - Bloomberg Gadfly

2018-01-11 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (164-2)

Valeant CEO Is in the Midst of the ‘Turnaround Opportunity of a Lifetime’ - Bloomberg

2018-01-10 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (164-1)

Valeant: What Does Papa's New Promise Mean For The Company?

2018-01-10 seekingalpha
Valeant Pharmaceuticals International Inc. (VRX) is a guest at the Annual J.P. Morgan Healthcare Conference in San Francisco where CEO Joseph C. Papa will provide an update for the company. Last February Papa delivered a promise to reduce Valeant's debt load by $5 billion by February's upcoming conference call in 2018. He has smashed his prediction out of the ballpark with the latest $300 million debt payment resulting in the company reducing its debt by more than $6. (165-0)

Valeant Pharmaceuticals (VRX) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow

2018-01-10 seekingalpha
The following slide deck was published by Valeant Pharmaceuticals International, Inc. in conjunction with this event. (165-0)

Shopify Inc Stock Is Headed for a New All-Time High

2018-01-10 investorplace
At its heart, the bull/bear battle over Shopify Inc (US) (NYSE:SHOP) stock is an argument over valuation. Over the past six months, that battle mostly has been a stalemate, with SHOP stock up modestly from early August, when it first cleared $100. (314-0)

Stock Research Report

Valeant Pharmaceuticals International, Inc. is a multinational, specialty pharmaceutical and medical device company that develops, manufactures, and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (“OTC”) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. We are diverse not only in our sources of revenue from our broad drug and medical device portfolio, but also among the therapeutic classes and geographies we serve. We generated revenues of $4,342 million and $4,792 million for the six months ended June 30, 2017 and 2016, respectively. Our portfolio of products falls into three reportable segments: (i) Bausch + Lomb/International, (ii) Branded Rx and (iii) U.S. Diversified Products.

  • The Bausch + Lomb/International segment consists of: (i) sales in the U.S. of pharmaceutical products, OTC products a...
Click for full article
CUSIP: 91911K102